RASSF4 inhibits colorectal cancer (CRC) cell proliferation and colony formation by suppressing the Hippo–YAP signaling pathway and its downstream target B-cell lymphoma 2 (Bcl-2), while upregulating p21 expression, thereby blocking the cell cycle at the G1/S phase and inhibiting the malignant progression of CRC [2]. Here, BCL2 is linked to colorectal carcinoma.